StreetInsider.com News Articles

Form 8-K Evofem Biosciences, Inc. For: Oct 09

Thu, 15 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261015/27193401.html

Evofem adds second manufacturer for Phexx, targets 40% cost cut

Wed, 23 Sep 2026 16:05:55 -0400

Evofem Biosciences (OTCID: EVFM) has contracted with a second pharmaceutical manufacturer to produce its prescription contraceptive vaginal gel Phexx, according to a company press release.

The San Diego-based company said the additional manufacturing source is expected to reduce unit costs by 40% or more and improve supply chain flexibility, subject to regulatory approval. The new manufacturer is intended to complement Evofem's existing manufacturing operations rather than replace them.

Evofem expects to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration in mid-2027 for Phexx produced at the additional facility. Commercial sales from the second supply source would

Form 8-K Evofem Biosciences, Inc. For: Sep 17

Wed, 23 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260923/27096766.html

Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global Growth Strategy

Wed, 23 Sep 2026 16:05:00 -0400

-- Additional manufacturing source expected to improve supply chain flexibility and reduce unit costs by 40% or more following regulatory approval --

SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) has achieved an important milestone in its strategy to support long-term growth, enhance manufacturing flexibility, and reduce costs. Evofem has contracted with a second pharmaceutical manufacturer to produce PHEXX® (lactic acid, citric acid and potassium bitartrate), its hormone-free, on-demand prescription contraceptive vaginal gel. Subject to regulatory approval, the additional manufacturing source is expected to provide meaningful economic benefits while

Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global Growth Strategy

Wed, 23 Sep 2026 16:05:00 -0400

-- Additional manufacturing source expected to improve supply chain flexibility and reduce unit costs by 40% or more following regulatory approval --

Form 10-Q Evofem Biosciences, Inc. For: Jun 30

Fri, 14 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26930423.html

Form 10-Q Evofem Biosciences, Inc. For: Jun 30

Fri, 14 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26930423.html

Form SCHEDULE 13D Evofem Biosciences, Inc. Filed by: Hub Cyber Security Ltd.

Tue, 04 Aug 2026 06:47:00 -0400

si-local-file:///var/storage/secattach/20260804/26861103.html

Form SCHEDULE 13D Evofem Biosciences, Inc. Filed by: Hub Cyber Security Ltd.

Tue, 04 Aug 2026 06:47:00 -0400

si-local-file:///var/storage/secattach/20260804/26861103.html

Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex

Thu, 23 Jul 2026 08:55:00 -0400

— Milestone highlights growing adoption while underscoring that millions of women remain unaware they have a hormone-free prescription contraceptive choice —

SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) today announced the shipment of its 500,000th box of PHEXX® (lactic acid, citric acid and potassium bitartrate), the first and only FDA-approved hormone-free, on-demand prescription contraceptive vaginal gel.

This milestone marks an important achievement for the company and reflects the growing number of women seeking contraception that aligns with their personal preferences, lifestyles, and healthcare needs. With 12 pre-filled PHEXX applicators per

Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex

Thu, 23 Jul 2026 08:55:00 -0400

— Milestone highlights growing adoption while underscoring that millions of women remain unaware they have a hormone-free prescription contraceptive choice —

Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex

Thu, 23 Jul 2026 08:55:00 -0400

— Milestone highlights growing adoption while underscoring that millions of women remain unaware they have a hormone-free prescription contraceptive choice —

Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex

Thu, 23 Jul 2026 08:55:00 -0400

— Milestone highlights growing adoption while underscoring that millions of women remain unaware they have a hormone-free prescription contraceptive choice —

Form 8-K Evofem Biosciences, Inc. For: Jul 20

Mon, 20 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260720/26789869.html

Form 8-K Evofem Biosciences, Inc. For: Jul 20

Mon, 20 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260720/26789869.html

Form 8-K Evofem Biosciences, Inc. For: Jul 08

Tue, 14 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260714/26768645.html

Form 8-K Evofem Biosciences, Inc. For: Jul 08

Tue, 14 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260714/26768645.html

Evofem Biosciences (EVFM) Misses Q1 EPS by 4c

Mon, 18 May 2026 16:40:49 -0400

Evofem Biosciences (OTC: EVFM) reported Q1 EPS of ($0.04). Revenue for the quarter came in at $900 thousand.

For earnings history and earnings-related data on Evofem Biosciences (EVFM) click here.

Form 8-K Evofem Biosciences, Inc. For: May 18

Mon, 18 May 2026 08:56:00 -0400

si-local-file:///var/storage/secattach/20260518/26510969.html

Form 8-K Evofem Biosciences, Inc. For: May 18

Mon, 18 May 2026 08:56:00 -0400

si-local-file:///var/storage/secattach/20260518/26510969.html

Evofem Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 18 May 2026 08:55:00 -0400